Document Detail


Do angiotensin receptor blockers protect against Alzheimer's disease?
MedLine Citation:
PMID:  23532556     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Because growing evidence suggests that angiotensin II receptor blockers (ARBs) effectively inhibit oxidative stress, amyloid beta protein (Aβ) metabolism, and tau phosphorylation in animal brains, ARBs are considered to be a potential candidate for the treatment of Alzheimer's disease (AD). Consistent with such basic studies, two recent observational studies and a small prospective, randomized, open-label trial have shown the effectiveness of ARBs in preventing AD and/or slowing its progression. Nonetheless, large clinical trials have not shown their effectiveness, but their results are debatable because of short follow-up durations and heterogeneity of the cognition assessments used in the studies. Because a recent analysis of the Honolulu-Asia Aging study showed that abnormalities of the serum Aβ level begin approximately 15 years before the diagnosis of AD, long-term clinical trials assessing dementia as a primary endpoint with sensitive measurements of cognition and brain imaging techniques will clarify the effectiveness of ARBs in AD treatment.
Authors:
Hitomi Kurinami; Munehisa Shimamura; Naoyuki Sato; Hironori Nakagami; Ryuichi Morishita
Related Documents :
24177486 - The evaluation of a telephonic wellness coaching intervention for weight reduction and ...
8016286 - The emergence of gender differences in depression during adolescence.
23667356 - Randomized clinical trial of a primary care internet-based intervention to prevent adol...
23597486 - Anosognosia and depression in patients with alzheimer's dementia.
6532286 - The effect of topical indomethacin ophthalmic solution in maintaining mydriasis during ...
10217056 - Cholinergic markers in elderly patients with early signs of alzheimer disease.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs & aging     Volume:  30     ISSN:  1170-229X     ISO Abbreviation:  Drugs Aging     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-05-24     Completed Date:  2013-10-31     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  9102074     Medline TA:  Drugs Aging     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  367-72     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aging
Alzheimer Disease / prevention & control*
Amyloid beta-Peptides / metabolism
Angiotensin Receptor Antagonists / therapeutic use*
Animals
Benzimidazoles / therapeutic use
Benzoates / therapeutic use
Cerebrovascular Circulation / drug effects
Clinical Trials as Topic
Cognition / drug effects
Disease Progression
Humans
Oxidative Stress
Phosphorylation
Chemical
Reg. No./Substance:
0/Amyloid beta-Peptides; 0/Angiotensin Receptor Antagonists; 0/Benzimidazoles; 0/Benzoates; U5SYW473RQ/telmisartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pill Burden in Hypertensive Patients Treated with Single-Pill Combination Therapy - An Observational...
Next Document:  Cabazitaxel: A Guide to Its Use in Hormone-Refractory Metastatic Prostate Cancer.